Organization
Alexion Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Alexion Pharmaceuticals, Inc.
... families, is dependent on us working together to hold companies such as Alexion [Pharmaceuticals Inc.] accountable for the outrageous prices they set," Mr. Dix told ...
... vice president and therapeutic area head for the metabolic business unit at Alexion Pharmaceuticals, Mr. Bjarke was responsible for asfotase-alfa for the treatment hypophosphatasia and ...
... President of Finance in October. Mr. Phillips was most recently employed by Alexion Pharmaceuticals where he served as Chief Accounting Officer and then SVP of ...
... vice president and therapeutic area head for the metabolic business unit at Alexion Pharmaceuticals, Mr. Bjarke was responsible for asfotase-alfa for the treatment hypophosphatasia and ...
... NEW HAVEN - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that Francois Nader, M.D., has been appointed ...
... pharmaceutical industry and public accounting practice. Most recently, he was employed by Alexion Pharmaceuticals ("Alexion"), Inc, a Nasdaq-listed company, where he served as Chief Accounting ...
... Pioneering. Prior to Flagship, Dr. Springhorn spent more than 20 years at Alexion. He was one of the original scientists at Alexion as well as ...
... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced that more than 1,300 employees are rallying together in ...
... trials for paroxysmal nocturnal hemoglobinuria (PNH) and is vying to take on Alexion’s Soliris (eculizumab), a C5 inhibitor which is currently the only FDA-approved drug ...
... NEW HAVEN, Conn. - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that new interim data show that 80% of ...
... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Francois Nader, M.D., has been appointed to ...
... NEW HAVEN, Conn. - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers will present new data from two ...
... Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that new interim data show that 80% of ...
... Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that researchers will present new data from two ...
... Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at the 26th Annual ...
... NEW HAVEN, Conn. - Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2017. ...
... Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the third quarter of 2017. ...
... It took longer than some industry watchers expected, but Alexion has another indication for lead med Soliris in the bag. On Monday, ...
... Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) ...
... Katie Archer Alexion Pharmaceuticals Striving to make a local presence for a global group of ...
... System, West Sacramento; and * Katie Archer, director of global benefits, Alexion Pharmaceuticals Inc., New Haven, Conn. Massachusetts focused on providing a greater opportunity to ...
... abuses. In an unprecedented move, Canadian regulators recently ordered American pharmaceutical company Alexion to lower the price of its breakthrough treatment for a rare blood ...
... LLC ("KSF"), announces that KSF has commenced an investigation into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN). Since late 2016, the Company has been the subject of ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤